Anika Therapeutics (ANIK) Price to Sales (2010 - 2026)

Anika Therapeutics (ANIK) has reported Price to Sales for 17 consecutive years, with 6.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales rose 11.07% year-over-year to 6.0 in Q2 2026; TTM through Jun 2026 was 1.62, a 21.86% increase from a year earlier, with the FY2025 full-year figure at 1.18, down 40.22% from the prior year.
• Price to Sales was 6.0 for Q2 2026 at Anika Therapeutics, down from 6.54 in the prior quarter.
• Over five years, Price to Sales peaked at 12.97 in Q1 2024 and troughed at 155.33 in Q4 2022.
• A 5-year average of 7.56 and a median of 7.99 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales plunged 1175.34% in 2022 and soared 106.77% in 2024, its largest moves.
• Over 5 years, Price to Sales stood at 155.33 in 2022, then rose by 26.23% to 114.59 in 2023, then soared by 106.77% to 7.75 in 2024, then tumbled by 43.77% to 4.36 in 2025, then surged by 37.72% to 6.0 in 2026.
• The last three Price to Sales figures came in at 6.0 (Q2 2026), 6.54 (Q1 2026), and 4.36 (Q4 2025), per Business Quant data.